Several brokerages have updated their stock price recommendations and targets. Adamis Pharmaceuticals (NASDAQ: ADMP) over the past few weeks:
- 05/30/2022 – Adamis Pharmaceuticals is now covered by analysts at StockNews.com. They put a “sell” mark on the stock.
- 05/27/2022 – Adamis Pharmaceuticals has been updated by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a price target of $0.50 on the stock. According to Zacks, “Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged in the research, development and commercialization of prescription drugs for the treatment of viral infections. Adamis Pharmaceuticals is comprised of two wholly owned subsidiaries proprietary, Adamis Labs and Adamis Viral Therapies.Adamis Labs is a commercial-stage specialty pharmaceutical company targeting high prescribing physicians in the Allergy, Respiratory and Pediatric Medicine market segments.To complement and enhance the sales efforts of Adamis Labs , Adamis Viral Therapies is focused on the development of patented and highly regarded vaccine technology which Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. pharmaceuticals and nutraceuticals.The company has its headquarters in Del Mar, California. “
- 26/05/2022 – Adamis Pharmaceuticals has been downgraded by analysts at Zacks Investment Research from a “buy” odd to a “hold” odd. According to Zacks, “Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged in the research, development and commercialization of prescription drugs for the treatment of viral infections. Adamis Pharmaceuticals is comprised of two wholly owned subsidiaries proprietary, Adamis Labs and Adamis Viral Therapies.Adamis Labs is a commercial-stage specialty pharmaceutical company targeting high prescribing physicians in the Allergy, Respiratory and Pediatric Medicine market segments.To complement and enhance the sales efforts of Adamis Labs , Adamis Viral Therapies is focused on the development of patented and highly regarded vaccine technology which Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. pharmaceuticals and nutraceuticals.The company has its headquarters in Del Mar, California. “
- 05/22/2022 – Adamis Pharmaceuticals is now covered by analysts at StockNews.com. They put a “sell” mark on the stock.
- 05/14/2022 – Adamis Pharmaceuticals is now covered by analysts at StockNews.com. They put a “sell” mark on the stock.
- 05/06/2022 – Adamis Pharmaceuticals is now covered by analysts at StockNews.com. They put a “sell” mark on the stock.
- 04/28/2022 – Adamis Pharmaceuticals is now covered by analysts at StockNews.com. They put a “sell” mark on the stock.
- 04/20/2022 – Adamis Pharmaceuticals is now covered by analysts at StockNews.com. They put a “sell” mark on the stock.
Adamis Pharmaceuticals Stock opened at $0.49 on Wednesday. The company’s fifty-day simple moving average is $0.47 and its 200-day simple moving average is $0.59. Adamis Pharmaceuticals Co. has a 1-year low of $0.31 and a 1-year high of $1.48.
Adamis Pharmaceuticals (NASDAQ: ADMP – Get a rating) last announced its results on Monday, May 16. The specialty pharma company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.04). Adamis Pharmaceuticals had a negative return on equity of 100.63% and a negative net margin of 585.90%. On average, research analysts expect Adamis Pharmaceuticals Co. to post -0.15 EPS for the current year.
A number of institutional investors and hedge funds have recently changed their positions in the stock. State Street Corp increased its stake in Adamis Pharmaceuticals by 13.1% in the first quarter. State Street Corp now owns 475,373 shares of the specialty pharmaceutical company worth $271,000 after acquiring an additional 55,168 shares during the period. Capital CS Group LLC bought a new position in Adamis Pharmaceuticals in Q1 worth $40,000. Virtu Financial LLC increased its stake in Adamis Pharmaceuticals by 9.6% in the 4th quarter. Virtu Financial LLC now owns 224,561 shares of the specialty pharmaceutical company worth $136,000 after acquiring an additional 19,691 shares during the period. JPMorgan Chase & Co. increased its stake in Adamis Pharmaceuticals by 735.2% in the 4th quarter. JPMorgan Chase & Co. now owns 218,573 shares of the specialty pharmaceutical company worth $132,000 after acquiring an additional 192,403 shares during the period. Finally, Avantax Advisory Services Inc. increased its position in Adamis Pharmaceuticals by 68.8% in the 4th quarter. Avantax Advisory Services Inc. now owns 54,000 shares of the specialty pharmaceutical company worth $33,000 after purchasing an additional 22,000 shares in the last quarter. Hedge funds and other institutional investors own 9.52% of the company’s shares.
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory and inflammatory disease in the United States. The Company’s product candidates include SYMJEPI epinephrine prefilled syringe injectable products for the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhalation preparations for the treatment of asthma; and naloxone injection for the treatment of an opioid overdose.
Featured articles
Get news and reviews for Adamis Pharmaceuticals Co Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Adamis Pharmaceuticals Co and related companies with MarketBeat.com’s free daily email newsletter.
